PAKOLA STEVE 4

What Happened
Steve Pakola, Chief Medical Officer of REGENXBIO, reported the sale of 5,124 shares on 2026-03-10. The shares were disposed at $10.35 each for proceeds of approximately $53,033. This was a sale (not a purchase), which is often a routine liquidity event rather than a bullish signal.

Key Details

• Transaction date: 2026-03-10; Report filed: 2026-03-12 (timely filing).
• Price and size: 5,124 shares sold at $10.35 per share; total proceeds ≈ $53,033.
• Type: Reported as an open market or private sale (Form 4 shows "S").
• Footnote: Transaction effected pursuant to a Rule 10b5-1 trading plan (prearranged trading).
• Shares owned after transaction: Not reported in this filing.

Context
A Rule 10b5-1 plan allows insiders to execute predetermined trades and helps avoid questions about trading on material nonpublic information; sales under such plans are generally considered routine. For retail investors, purchases by insiders often carry more informational weight than routine sales; this single, modest-sized sale does not by itself indicate a change in company prospects.